We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be ...
Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.
“While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that an ...
SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target ...
The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the ...
Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their ...
NaV1.7 inhibitors are a class of drugs that can potentially treat pain disorders without causing motor or cognitive impairment. In the preclinical studies with rodents, the company's nerve block ...
“While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback